drugset / Trial / NCT04565145
Biomarker Changes and Anxiolytic Effects-Phase 2
Phase 2
Completed
39 enrolled
University of Florida
National Center for Complementary and Integrative Health (NCCIH) · collabThorne HealthTech, Inc · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
This study will examine the utility of plasma and urinary based biomarkers for the anxiolytic properties of kava. The investigators will conduct a one week, double blind, randomized placebo controlled trial of kava, dosed at three 75 mg capsules per day, vs placebo, in adults with generalized anxiety disorder.
Timeline
- Start
- 2021-04-05
- Primary completion
- 2023-07-01
- Completion
- 2023-07-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Kava | Traditional medicine (herbal / TCM) | 75 mg | — |
Indications
No indication recorded.